Identifying cohesion of barriers and viewpoints across different stakeholders in drug repurposing

Authors

• SR Strongin
• KC Tumas
• A Simeonov
• EA Mathé

Abstract

A qualitative study was developed to capture diverse viewpoints on the challenges in the translational processes spanning preclinical to clinical stages of drug repurposing. Using the grounded theory research model, this IRB exempt study was designed to conduct thematic coding analysis building upon multiple rounds of interviews. This study relies on diverse interviewees comprised of experts in distinctive stages of drug repurposing, with experience across industries, from multiple disease specialties, at varying stages of career development, and with different demographic identities. Questions were designed to ascertain the unique perspectives that each stakeholder brings to drug repurposing including assay development, screening, bioinformatics, clinical practice, clinical trials, regulatory, and patient advocacy. Analyses on background, personal experience, challenges, and potential solutions will be conducted to understand individual stakeholder viewpoints and identify areas of cohesion to improve drug repurposing.

This project is a part of CURE ID, a program developed in partnership between the U.S. Food and Drug Administration and the National Center for Advancing Translational Sciences. CURE ID is a data collection tool for real world evidence of drug repurposing. The program is invested in identifying drug repurposing opportunities globally, particularly in diseases that lack approved therapies and have high unmet medical needs.

The data from this study presents an opportunity for a collaborative effort to reassess the current landscape and mechanisms to streamline the preclinical to clinical translational process of drug repurposing.

Scientific Focus Area: Social and Behavioral Sciences

This page was last updated on Tuesday, August 6, 2024